Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma 
Welcome,         Profile    Billing    Logout  
 23 Diseases   2 Trials   2 Trials   33 News 
  • ||||||||||  Journal:  Intravitreal steroid implants in the management of noninfectious intermediate and posterior uveitis. (Pubmed Central) -  Dec 26, 2024   
    Dexamethasone implants favor the therapeutic goal of prevention of recurrences, whereas the use of fluocinolone implants helps to attain better visual outcomes due to their longer duration of action. Thus, the review provides recent literature supporting the role and indication of sustained release intravitreal implants in the management of noninfectious intermediate and posterior uveitis.
  • ||||||||||  Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma
    Journal:  Retisert implantation without incisional sclerotomy in patients with uveitis and extensive pars plana fibrosis. (Pubmed Central) -  Aug 27, 2024   
    Retisert can be implanted via the anterior chamber in patients with extensive fibrosis in the pars plana and pars plicata regions. This approach may minimize the risk of retinal traction and damage to the implant when compared to the traditional full-thickness sclerotomy method in these high-risk cases.
  • ||||||||||  Review, Journal, Combination therapy:  Therapeutic Effects of Combination Therapy and Photobiomodulation Therapy on Retinal Regeneration. (Pubmed Central) -  Feb 7, 2023   
    We investigated the effects of various lasers photocoagulation such as Focal and/or grid macular laser, subthreshold micropulse laser (SMPL), as well as intravitreal pharmacotherapies with triamcinolone acetonide, and fluocinolone, and extended released intraocular implants such as Ozurdex, Retisert, Iluvien, and anti-vascular endothelial growth factors such as bevacizumab (Avastin), Eyela, and Lucentis...Therefore, combining the medication with a laser is much more reasonable than each alone. Also, the subthreshold photocoagulation laser (670 nm) is better at reducing the central macular thickness (CMT) and improving VA than the micro pulse yellow laser and pan-retinal photocoagulation (PRP).
  • ||||||||||  Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma, Ozurdex (dexamethasone intravitreal implant) / AbbVie, Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Long-term Dose-controllable Drug Delivery Implant (F0147) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_4702;    
    The drug delivery system was safe and stable against leakage for 6 months. The light-activated drug delivery system that we developed will provide tightly-controlled release without burst release.
  • ||||||||||  Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
    Journal:  Yutiq - another fluocinolone intravitreal implant for uveitis. (Pubmed Central) -  Sep 30, 2021   
    The approach described is potentially safe and effective in preventing phthisis and membrane formation in uveitis-associated hypotony and keratopathy. No abstract available
  • ||||||||||  Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma
    Trial completion, Trial completion date, Trial primary completion date:  Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant (clinicaltrials.gov) -  Jun 21, 2019   
    P=N/A,  N=98, Completed, 
    It's extended-release format for up to 3 years benefits to the patient and carer as it means fewer injections and visits to the clinic. Recruiting --> Completed | Trial completion date: May 2018 --> Jun 2019 | Trial primary completion date: Mar 2018 --> Mar 2019
  • ||||||||||  Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant (clinicaltrials.gov) -  Jun 21, 2019   
    P=N/A,  N=3, Completed, 
    Recruiting --> Completed | Trial completion date: May 2018 --> Jun 2019 | Trial primary completion date: Mar 2018 --> Mar 2019 Not yet recruiting --> Completed | N=80 --> 3 | Trial completion date: Aug 2020 --> Mar 2019 | Trial primary completion date: Jul 2020 --> Sep 2018
  • ||||||||||  Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma
    Trial initiation date, Trial primary completion date:  Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant (clinicaltrials.gov) -  Apr 25, 2017   
    P=N/A,  N=100, Recruiting, 
    Not yet recruiting --> Completed | N=80 --> 3 | Trial completion date: Aug 2020 --> Mar 2019 | Trial primary completion date: Jul 2020 --> Sep 2018 Initiation date: Aug 2006 --> Feb 2016 | Trial primary completion date: Apr 2017 --> Mar 2018
  • ||||||||||  Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma
    Trial completion:  Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO) (clinicaltrials.gov) -  Oct 22, 2012   
    P0,  N=30, Completed, 
    Recruiting --> Completed Recruiting --> Completed
  • ||||||||||  Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma
    Trial completion:  Prophylactic Anecortave Acetate in Patients With a Retisert Implant (clinicaltrials.gov) -  Jun 2, 2012   
    P1,  N=12, Completed, 
    N=24 --> 12 Active, not recruiting --> Completed